Elevate Credit has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company has decided to price its 12.4 million shares at $6.50 per share, with an overallotment option for an additional 1.86 million shares. At this price the entire offering is valued up to $92.69 million. The company intends to list its shares on the New York Stock Exchange under the symbol ELVT.
The underwriters for the offering are UBS Investment Bank, Credit Suisse, Jefferies, Stifel and William Blair.
The company had decided to postpone its offering back in January, but now it is back on the table.
The company offers technology-driven online credit solutions to non-prime consumers. This is for consumers with credit scores of less than 700 and who are not well-served by either banks or legacy non-prime lenders. These non-prime consumers approximately 170 million people in the United States and United Kingdom now represent a larger market than prime consumers but are difficult to underwrite and serve with traditional approaches.
Top 5 Value Stocks To Invest In Right Now: Lucas Energy, Inc.(LEI)
- [By Garrett Baldwin]
The Interior Department is in charge of managing regulations around oil and gas drilling around the nation. Currently, the favorite appears to be Forrest Lucas, the 74-year-old founder of Lucas Energy Inc. (NYSEMKT: LEI). A career energy executive, Lucas recently told Investors Business Daily that he would be interested in the job because “it’s a very important position and you need to have someone in there who knows what they’re doing.” However, Lucas has never actually met Trump in person.
Top 5 Value Stocks To Invest In Right Now: Female Health Company (The)(FHCO)
- [By Lisa Levin]
Shares of Female Health Co (NASDAQ: FHCO) were down 15 percent to $1.46 as the company reported that it has entered into a merger agreement with Aspen Park Pharma.
Top 5 Value Stocks To Invest In Right Now: Nuveen Municipal Value Fund Inc.(NUV)
- [By Donald van Deventer]
The latest implied forward rate forecast from Kamakura Corporation shows projected 10-year U.S. Treasury yields differing -0.07% to 0.03% from last week while fixed rate mortgage yields varied by -0.01% to 0.08%. Mortgage yields, determined by the Monday through Wednesday weekly survey of the Federal Home Loan Mortgage Corporation, lag Treasury movements simply because of the 3-day yield calculation used in the Primary Mortgage Market Survey. The 10-year U.S. Treasury yield is projected to rise from 2.92% at Thursday’s close (down 0.06% from last week) to 3.374% (down 0.06% from last week) in one year. The 10-year U.S. Treasury yield in ten years is forecast to reach 4.639%, 1 basis point lower than last week. The 15-year fixed rate mortgage rate is forecast to rise from the effective yield of 3.69% on Thursday (down 0.001% from last week) to 4.222% (down 0.006% from last week) in one year and 6.29% in 10 years, up 0.038% from last week. We explain the background for these calculations in the rest of this note, along with some mortgage servicing rights metrics. The forecast allows investors in exchange traded U.S. Treasury funds (TLT) (TBT), total return bond funds (BOND), municipal bonds (NUV) and exchange traded mortgage funds (REM) to assess likely total returns over the next 120 months. Treasury-related exchange traded funds affected by the forward rates include:
Top 5 Value Stocks To Invest In Right Now: Canterbury Park Holding Corporation(CPHC)
- [By Sally Jones]
Canterbury Park Holding Corporation (CPHC) Market Cap $46.35 Million
Canterbury Park Holding Corporation is up 2% over 12 months. The company has a market cap of $46.35 million; its trades around $11.16 with a P/E ratio of 59.30 and a P/B of 1.70.
Top 5 Value Stocks To Invest In Right Now: Merck & Company, Inc.(MRK)
- [By Keith Speights]
With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.
- [By Shanthi Rexaline]
See also: 3 Reasons Alcoa Is No Longer The Curtain-Raising Event Of Earnings Season
Company: E I Du Pont De Nemours And Co (NYSE: DD). Date of Reporting: Tuesday, before the market open. EPS Estimate vs. Year-ago EPS: $1.29 versus $1.24. Revenue Estimate: $7.29 billion versus $7.06 billion. Stock Gain/Loss (year to date): 14.97 percent.
Company: AT&T Inc (NYSE: T). Date of Reporting: Tuesday, after the market close. EPS Estimate vs. Year-ago EPS: $0.74 versus $0.72. Revenue Estimate: $39.82 billion versus $40.52 billion. Stock Gain/Loss (year to date): (-14.6 percent).
Company: The Coca-Cola Co (NYSE: KO). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $0.58 versus $0.60. Revenue Estimate: $9.65 billion versus $11.52 billion. Stock Gain/Loss (year to date): 8.32 percent.
Company: Boeing Co (NYSE: BA). Date of Reporting: Wednesday, before the market open. EPS Estimate vs. Year-ago EPS: $2.31 versus $2.47. Revenue Estimate: $23.07 billion versus $24.75 billion. Stock Gain/Loss (year to date): 36.03 percent.
9. Procter & Gamble
Company: Procter & Gamble Co (NYSE: PG). Date of Reporting: Thursday, before the market open. EPS Estimate vs. Year-ago EPS: $0.78 versus $0.79. Revenue Estimate: $16.02 billion versus $16.1 billion. Stock Gain/Loss (year to date): 4.98 percent.
- [By The Ticker Tape]
LLY recently suffered a setback when approval for the company’s new arthritis drug, co-developed with Incyte Corporation (NASDAQ: INCY), faced delays from the FDA. LLY and INCY disagreed with the FDA’s findings in a company press release and are confident the drug will still be approved in the future. Despite the company’s confidence in the drug, LLY stock dropped about 5% in trading the day the news came out. Even with that drop, it’s still up a little over 11% on the year, outperforming the S&P 500 (SPX) and some of its pharma peers: Merck & Co., Inc. (NYSE: MRK), Pfizer Inc. (NYSE: PFE), and Johnson & Johnson (NYSE: JNJ).
- [By Matthew Briar]
Kudos to Merck & Co., Inc. (NYSE:MRK) and Pfizer Inc. (NYSE:PFE) for taking a leap forward in the war against diabetes. The two competitors-turned-partners for one joint venture recently announced the FDA and the European equivalent has accepted an application for permission to sell ertugliflozin and a couple of its derivatives. All the drugs/combos in question are part of the SGLT2 family, which essentially induce the kidneys to filter sugar out of the bloodstream for diabetics whose pancreas isn’t processing that sugar properly.
It’s an interesting approach, though not one without a potential downside. By forcing the kidneys to do something they weren’t meant to do, eventually, could pose new problems.
Cell MedX Corp (OTCMKTS:CMXC) is taking an entirely different approach to the treatment of diabetes. Rather than work around a failing pancreas as Merck and Pfizer have, Cell MedX is aiming to fix what’s broken for diabetics. That is, the company aims to restore a body’s cells that properly process sugar by turning them back “on” again using mild electrical currents.
As much as biologists and the healthcare industry know about the human body, new discoveries are being made all the time regarding our makeup. One of the more recent medical revelations was figuring out animals are not just a collection of chemicals and organic matter, but also electrical impulses. Yes, the human body creates electricity, but more than that, a body can benefit from mild electrical currents, as an electrical charge can put a damaged cell back into its natural, healthy state.
It may seem like a crazy idea at first, but know the FDA has already given the science of electromedicine the nod of approval as a treatment for chronic pain (called the Cefaly, if you’re curious), and some major companies are wading deeper into electromedicine waters.
As Scientific American’s Daisy Yuhas noted back in 2013:
- [By Nelson Hem]
In Reshma Kapadia's "Hersh Cohen Shares His Top Dividend Picks," see what ClearBridge Investments fund manager Harry "Hersh" Cohen sees in top dividend payers such as Merck & Co., Inc. (NYSE: MRK) and Schlumberger Limited. (NYSE: SLB). He also shares his thoughts on whether the market is putting in a top, what contributes to market complacency and more.